Panel Discussion: The R&D reset: Navigating volatility, regulation and rising complexity

Panellists in this video: • Dr Pirthi Pal Singh, President & Group R&D Head, Tirupati Group (Moderator) • Mr Shrenik Kole, VP and Head- Sterile Product Development, Micro Labs • Dr Sachin Mundade, VP – R&D, Micro Labs • Dr Krishna Murthy Bhavanasi, VP – R&D, Lotus Pharmaceutical • Mr Yogesh Joshi, Associate Director & Head (Formulation Development)/Head – Clinical Manufacturing, Piramal Pharma Solutions • Dr Arindam Halder, GM, Sun Pharmaceutical Industries • Mr Sandipan Roy, GM, Hetero Key Highlights: [1] Early-stage excipient compatibility, stability, and process studies are crucial for designing robust formulations and reducing development risks. [2] AI, machine learning, and digital tools can accelerate formulation optimisation, improve decision-making, and shorten development timelines. [3] Integrating regulatory intelligence from the beginning helps navigate global compliance requirements and speeds up product development. [4] Innovation in complex formulations requires close collaboration between R&D, regulatory, clinical, IP, and technology teams rather than working in silos. [5] Drug repurposing and long-acting delivery systems present significant opportunities to create differentiated, high-value products. [6] Building pharmacology, toxicology, and clinical expertise alongside formulation capabilities is essential to minimise costly late-stage failures. [7] Strategic partnerships with academia, CDMOs, and specialised service providers are increasingly important to access capabilities, manage complexity, and improve development efficiency. The post Panel Discussion: The R&D reset: Navigating volatility, regulation and rising complexity appeared first on Express Pharma.